Listed

Vertex Pharmaceuticals Inc / Ma: Form 10-Q for the period ended Mar 31, 2018

Filed with the SEC on Apr 27, 2018 and accepted by EDGAR at Apr 27, 2018, 20:36 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2018-01-01 to 2018-03-31$640.8mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development3 months2018-01-01 to 2018-03-31$310.6mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2018-01-01 to 2018-03-31$129.8mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2018-01-01 to 2018-03-31$128.9mus-gaap:OperatingIncomeLoss
Income tax3 months2018-01-01 to 2018-03-31−$12.7mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2018-01-01 to 2018-03-31$210.3mus-gaap:NetIncomeLoss
Diluted EPS3 months2018-01-01 to 2018-03-31$0.81us-gaap:EarningsPerShareDiluted
Basic EPS3 months2018-01-01 to 2018-03-31$0.83us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2018-01-01 to 2018-03-31258,526,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2018-01-01 to 2018-03-31$252.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2018-01-01 to 2018-03-31$29.3mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases3 months2018-01-01 to 2018-03-31$10.0mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2018-03-31$2.00bnus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-03-31$3.04bnus-gaap:AssetsCurrent
Total assetsAt period end2018-03-31$3.95bnus-gaap:Assets
Current liabilitiesAt period end2018-03-31$827.3mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-03-31$1.52bnus-gaap:Liabilities
Shareholders' equityAt period end2018-03-31$2.40bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000875320-18-000014. Last ingested by Listed: Nov 14, 2026, 23:22 ET. Listed shows no prices and gives no investment advice.